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Summary 
 
Origanum majorana Linn. (Family- Labiatae) is a herb, commonly grows in Mediterranean regions. The plant 
has been used in the treatment of diseases related to the nervous system as an antiepileptic and sedative drug in 
traditional medicines. In this study, anticonvulsant and sedative activities for different extracts of aerial parts 
(leaves and stems) of O. majorana are evaluated. An anticonvulsant effect of O. majorana was investigated 
using the Pentylenetetrazole (PTZ) and maximal electroshock (MES) test  The pet ether, chloroform, acetone, 
methanol and aqueous extracts (PEOM, CEOM, ACEOM, MEOM, and AQEOM respectively) of O. majorana 
exhibited anticonvulsant effect in both the PTZ and MES induced seizure models at the doses of 250 and 500 
mg/kg, i.p. The extracts of O. majorana delayed the onset of seizures and reduced the duration of seizures in 
PTZ test and decreased the duration of seizures in MES test compared to the control group. The CEOM 
exhibited maximum reduction (58.47 and 44.83% in PTZ and MES test respectively) in the duration of seizures, 
hence it was processed to isolate triterpenoic acid fraction (TAF) which contained substantial amount of ursolic 
acid. The TAF exhibited maximum reduction (64.54 and 59.31% in PTZ and MES test respectively) in the 
duration of seizures compared to the other extracts of O. majorana. Also, the test extracts decreased the latency 
and increased the duration of total sleeping time significantly.  The antagonism of chemically and electrically 
induced seizures that O. majorana extracts possess anticonvulsant activity. Presence of flavonoids, steroids, 
triterpenoids and essential oil may be responsible for the anticonvulsant activity of this plant. 
 
 
Keywords: Anticonvulsant, Labiatae, maximal electroshock, Origanum majorana, Pentylenetetrazole, 
Sedative, sodium pentobarbitone.  
 
Address for reprint and correspondence: 
Dr. Chhaya H. Gadgoli 
Professor of Pharmacognosy 
Saraswathi Vidya Bhavan’s College of Pharmacy,  
Sankara Nagar, Kalyan-Shill Road, Sonarpada,  
Dombivli (E), Thane 421 203, Maharashtra, India. 
Email: chhayahg@rediffmail.com Phone no.:+91-0251-2871785  Fax no.:+91-251-2871243 
 
 
 
Pharmacologyonline 1: 64-78 (2007)                                                                 Deshmane et al. 
 65
Introduction 
Marjoram, O. majorana is a tender perennial herb of the mint family (Labiatae), which was formerly classified 
as Majorana hortensis Moench (Vagi et al,2002). Majorana is a fairly small slightly sprawling, soft grey-green 
leafed plant, to 2 feet/ 60 cm (smaller if grown as an annual) with ‘knots’ of fairly insignificant pink or white 
flower or weiry erect stems in mild summer. It is widely used in traditional medicines as well as in the food and 
cosmetic industries. The herb has carminative, antispasmodic, diaphoretic and diuretic properties (Vagi et al, 
2005). In particular sweet marjoram herb contains upto 3% volatile oil, flavonoid glycosides, tannin, steroids 
(e.g. ß-sitosterol) and triterpenoids (oleanolic acid and ursolic acid) (Leung et al, 1996). It also contains linalool, 
sabinol, terpinen-4-ol, thujanol, camphor, carvacrol, eugenol, pinene, alpha terpenene (Shirley, 1993).The 
different extracts of O. majorana possess antioxidant, antimicrobial and antiinflammatory activities (Heo et al, 
2002; Deans et al, 1990;  Ezzeddine et al, 2001). The herb is used in some parts of Punjab as pot herb like mint. 
It is a good general tonic, with carminative, diaphoretic, diuretic, expectorant and stimulant effect (Nadkarni et 
al,1999). It has a stronger effect on the nervous system however no experimental evidence reported in the 
literature (Chevallier, 1996) 
 The epilepsy belongs to the most encountered neurological conditions since it affects approximately 1% 
of the world population. About 75-80% of epileptic patients may be provided with adequate seizure control with 
the help of conventional allopathic antiepileptic drugs. There is therapeutic failure in 20-25% of patients which 
stimulated exhaustive research on novel antiepileptic drugs (Piotr  et al, 2005). For centuries, herbs have been 
used in traditional medicines to treat a wide range of ailments, including central nervous system disorders such 
as epilepsy. However, the mechanism of action by which these botanicals exert their therapeutic effects has not 
been completely elucidated. Use of O. majorana in the traditional medicine for the treatment of epilepsy and 
lack of experimental evidence motivated us to undertake the present investigation.  
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Methods 
Drugs and chemicals 
Pentylenetetrazole was purchased from Sigma-Aldrich chemical company, USA. Diazepam and Phenytoin were 
obtained from Ranbaxy, Delhi, India. Sodium pentobarbitone was purchased from BDH chemicals, Kandivli, 
Mumbai, India. The solvents and chemicals used were of analytical grade. Ursolic acid standard was received 
from Sami Labs Limited, Banglore, India. 
Plant material and extraction procedure 
The dried aerial parts (leaves and stems) of O. majorana were collected from the local market, Mumbai and 
were authenticated by Dr. A. M. Mujumdar, Head Plant science division, at Agharkar Research Institute, Pune, 
India, in September 2005. The dried aerial parts of O. majorana were powdered. The powder was extracted 
successively with solvents of increasing polarity viz. pet ether (60-80oC), chloroform, acetone, methanol and 
water using soxhlet extraction apparatus. The extracts were concentrated under vaccum at (60±50C). The 
chloroform extract was processed to get a triterpenoic acid fraction (TAF). The extracts were suspended in 3% 
w/v acacia solution before administration to animals. 
Fractionation of Triterpenoic acid fraction 
The TAF was generated from chloroform extract. In brief, 8 g of dried chloroform extract was dissolved in 40 
ml of chloroform, which was subsequently treated with 40 ml of saturated sodium bicarbonate solution twice. 
The sodium bicarbonate fractions were separated and pooled. Triterpenoic acids were regenerated by acidifying 
the solution with concentrated hydrochloric acid followed by extraction in chloroform. The triterpenoic acids 
were obtained by evaporating chloroform under vacuum. The TAF was quantified for ursolic acid using HPTLC 
technique. 
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Animals 
Swiss albino mice of either sex (18-22 g) were used for the present study. Male mice are preferred for the 
electroshock test. The animals were housed in standard environmental conditions of temperature (22 ± 50C) and 
relative humidity (55 ± 15 %) with 12-h light-dark cycles. They were fed on conventional laboratory pelleted 
diet and water ad libitum. All the procedures were performed in accordance with the Committee for the Purpose 
of Control and Supervision of Experiments on Animals (CPCSEA) under Ministry of Animal Welfare Division, 
Government of India, New Delhi, India (CPCSEA, 2003). The Institutional Ethical Committee and in-charge of 
animal house of Sarawathi Vidya Bhavan’s College of Pharmacy, approved the experimental protocol. 
Quantification of ursolic acid using HPTLC  
Ursolic acid content of the test extracts of O. majorana were determined by HPTLC on 20x20 cm silica gel 60, 
F254 (Merck, Germany) plate, using chloroform: methanol (95:5) as the mobile phase and ursolic acid as 
reference standard. Application of samples was carried out using Linomat 5 applicator and CAMAG 3 
densitometer was used to analyze the plate (λmax-366 nm). 
Induction of Convulsive seizures 
Pentylenetetrazole (PTZ) induced convulsions 
Convulsive seizures were induced by intraperitoneal injection of PTZ (70 mg/kg, i.p.). The mice were divided 
into 14 groups of 6 each. Control group received vehicle (0.5 ml of 3% w/v acacia solution), other standard 
group received diazepam (10 mg/kg, i.p.) as reference standard and the remaining 12 groups were administered 
PEOM, CEOM, ACEOM, MEOM, AQEOM and TAF in doses of 250 and 500 mg/kg, i.p., 30 min prior to the 
administration of PTZ. The onset of general clonus was used as the end point. The general clonus was 
characterized by fore limb clonus followed by full clonus of the body. The time of onset and duration of clonic 
convulsions, and mortality protection were recorded (Vogel et al, 1997). Percentage reduction in duration of 
seizures is calculated by considering the duration of seizures in control group as 100%. 
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Electroshock induced convulsions 
The procedure was carried out as described by Taman (Toman et al,1964) and swinyard  et al (Swinyard et 
al,1952) The electrical stimulus (50 mA, 0.3 s) was applied 30 minutes after i.p injection of the O. majorana 
extracts through ear-clip electrodes using stimulator apparatus (KI 9531, Dolphin, Mumbai, India). Tonic hind 
limb extension was considered as the end point. Anticonvulsant activity was evaluated by determining two 
parameters viz: the electroconvulsive threshold and percentage reduction in seizure duration by MES test. The 
convulsive threshold was determined using electroshocks of various intensities. The convulsive threshold was 
determined and the protective effect of test extracts was assessed against maximal electroshock. (50 mA,0.3 s) 
induced convulsive seizures. 
In both cases, the animals were divided into 14 groups of 6 each, among which the 12 groups of mice were 
administered PEOM, CEOM, ACEOM, MEOM, AQEOM and TAF in doses of 250 and 500 mg/kg, i.p. each. 
Standard group received phenytoin (20mg/kg i.p.) and control group received vehicle (0.5ml of 3%w/v acacia 
solution). The time for the extract to reach the maximum effect was determined as 30 minute after i.p. injection.  
The threshold, duration of tonic convulsion and mortality protection were recorded (Hosseinzadeh et al,2003). 
Percentage reduction in duration of seizures is calculated by considering the duration of seizures in control 
group as 100%. 
Statistical analysis 
The data were expressed as the mean ±S.E.M. obtained from the number of experiments (n=6). One-way 
ANOVA with Dunnett's post test was performed using GraphPad Prism version 4.00 for Windows, GraphPad 
Software, San Diego California USA, www.graphpad.com. The Statistical significance was accepted at p<0.05. 
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Results 
Preliminary phytochemical screening 
The preliminary qualitative phytochemical analysis revealed that the extracts of O. majorana contained 
flavanoids, triterpenoids and steroids. 
 
HPTLC analysis  
In HPTLC analysis, ursolic acid was identified and quantified from each extract having RF value in the range 
from 0.4 to 0.45. The plot of the peak area of the ursolic acid Vs concentration (mcg) was straight line shown in 
the figure 1. R2=0.9966. The presence of ursolic acid in the extracts is shown in the figure 2 and its percentage 
in each extract is mentioned in table 1. 
 
Figure 1 Standard plot of ursolic acid. 
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Figure 2: Quantification of ursolic acid in the extracts of O. majorana. (λmax- 366 nm.) 
Presence of ursolic acid in the extracts is shown in the figure by arrow. 
U1: PEOM, U2: CEOM, U3: ACEOM, S1 to S5 (Concentration grading from 1 to 5 mcg): Ursolic acid 
(standard), U4: MEOM, U5: AQEOM, U6: TAF 
 
Table 1: The % w/w of ursolic acid present in O. majorana extracts. 
Extracts (%w/w) Ursolic acid  
PEOM 0.9 
CEOM 1.13 
ACEOM 0.11 
MEOM 0.34 
AQEOM - 
TAF 1.18 
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Effect of O. majorana extracts in PTZ test 
The results of the PTZ test are presented in Table 2. In animals treated with vehicle, clonic convulsions 
appeared at 78.50±2.69 s after PTZ injection (70 mg/kg, i.p.) and all animals died after seizures. The PEOM, 
CEOM, MEOM and TAF delayed the onset of seizures and decreased the duration of seizures significantly 
(p<0.05) as compared to the control group.  No extract had complete seizure and mortality protective effect but 
the CEOM and TAF showed maximum % reduction in the duration of seizures. Diazepam (10 mg/kg i.p.) 
inhibited seizures completely. 
Table 2: Effect of O.  majorana extracts in PTZ-induced seizure in mice. 
Treatmet 
Dose 
(mg/kg 
i.p.) 
Onset of 
seizure (s) 
Duration of 
seizure (s) 
(%) Reduction 
in duration of 
seizure  
(%) Mortality 
protection  
 
Control - 78.50 ±2.69 52.17±2.18 0 0 
Diazepam 10 - - 100 100 
PEOM 250 193.2±2.30** 32.17±2.35** 38.33 33.34 
PEOM 500 216.2±2.50** 26.50±3.08** 49.20 50 
CEOM 250 231.2±2.82** 26.83±2.05** 48.56 70 
CEOM 500 262.5±2.15** 21.67±1.80** 58.47 66.67 
ACEOM 250 97.83±2.76** 46.17±1.83* 11.50 16.67 
ACEOM 500 104.2±2.38** 43.17±0.94* 17.25 33.34 
MEOM 250 139.2±2.52** 35.67±2.24** 31.63 50 
MEOM 500 153.5±2.34** 29.17±2.53** 44.09 50 
AQEOM 250 111.8±2.38** 42.83±1.79* 17.89 33.34 
AQEOM 500 124.2±2.41** 39.50±1.52** 24.28 33.34 
TAF  250 270.3±2.64** 23.17±2.00** 55.59 66.67 
TAF 500 294.2±3.20** 18.50±1.87** 64.54 66.67 
Values are expressed as mean ± S.E.M. (n=6), *p<0.05, **P< 0.01 compared to control. 
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Effect of O. majorana extracts in MES test 
The results of the electroconvulsive threshold and maximal electroshock (50mA, 0.3 s) are showen in Table 3 
and 4 respectively. The PEOM, CEOM, MEOM and TAF showed significant change in the electroconvulsive 
threshold compared to the control group. 
       In the MES test the duration of hind limb tonic extension in mice treated with vehicle was 24.17±1.10 s. 
The PEOM. CEOM, MEOM and TAF at the dose of 500 mg/kg, i.p. exhibited significant reduction in the 
duration of seizures compared to control group. Also, no mortality was observed in case of all the tested extracts 
of O. majorana with MES ( 50 mA, 0.3 s). 
 
Discussion 
The present study indicated that all the test extracts of O. majorana possess significant anticonvulsant activity 
in PTZ and MES induced seizures at 500 mg/kg dose. Maximum reduction in seizure duration was shown by 
TAF (64.54 and 59.31 % in PTZ and MES tests respectively). The most popular and widely used animal seizure 
models are the traditional MES and PTZ test. The MES test is considered to be a predictor of likely therapeutic 
efficacy against generalized tonic-clonic seizures. By contrast PTZ test represents a valid model for human 
generalized myoclonic seizures and also generalized seizures of petit mal (Loscher et al,1998). Thus, our results 
suggest the O. majorana extracts may be effective against human generalized myoclonic seizures and also 
absence ones. PTZ a chemoconvulsant is reported to induce seizures by depressing chloride channel function by 
binding to picrotoxin site on the Gamma amino butyric acid (GABA) receptor complex (Kulkarni et al, 1993). It 
has been indicated that PTZ induced seizures can be prevented by drugs that enhance GABAA receptor-
mediated inhibitory neurotransmission (Rogawski et al, 1995; Macdonald et al, 1995).  Preliminary 
phytochemical analysis performed in this study showed that terpenoids, steriods and flavonoids are the major 
components of O. majorana extracts.  
Pharmacologyonline 1: 64-78 (2007)                                                                 Deshmane et al. 
 73
Table 3: Effect of O.  majorana extracts on the threshold of electroshock induced seizure in mice. 
Treatment 
Dose (mg/kg, 
i.p.) 
Electroconvulsive threshold (mA) 
Control - 9.50±0.50 
Phenytoin 20 21.50±0.61** 
PEOM 250 13.00±1.00* 
PEOM 500 13.50±0.67** 
CEOM 250 13.50±0.71** 
CEOM 500 13.50±1.02** 
ACEOM 250 10.00±0.63 
ACEOM 500 12.50±0.92 
MEOM 250 12.00±0.77 
MEOM 500 13.00±0.63* 
AQEOM 250 11.50±1.20 
AQEOM 500 12.00±1.09 
TAF  250 13.00±0.57* 
TAF 500 14.50±0.50** 
Values are expressed as mean ± S.E.M. (n=6), *p<0.05, **P< 0.01 compared to 
control 
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Table 4: Effect of O.  majorana extracts in MES-induced seizure in mice. 
Treatment 
Dose (mg/kg, 
i.p.) 
Duration of seizure (s)
(%) Reduction in 
duration of seizure 
Control - 24.17±1.10 0 
Phynetoin 20 7.16±1.18** 70.37 
PEOM 250 17.33±1.43* 28.28 
PEOM 500 15.67±1.54** 35.17 
CEOM 250 15.83±1.16** 34.48 
CEOM 500 13.33±0.71** 44.83 
ACEOM 250 18.83±1.40* 22.07 
ACEOM 500 18.17±1.22* 24.83 
MEOM 250 18.17±1.57* 26.21 
MEOM 500 15.50±1.28** 35.86 
AQEOM 250 18.67±1.54* 22.76 
AQEOM 500 17.37±1.36* 28.14 
TAF  250 12.83±1.30** 46.90 
TAF 500 9.83±0.94** 59.31 
Values are expressed as mean ± S.E.M. (n=6), *p<0.05, **P< 0.01 compared to control 
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 It is reported that anticonvulsant activity of terpene SL-1, a synthetic monoterpene homologue of 
GABA, demonstrated anticonvulsant activity in PTZ induced seizures (Librowski et al,2000). Linnalool is 
another terpene compound which has protective effect against PTZ induced seizures (Silva Brum et al, 2001). 
Moreover pinene, eugenol and methyleugenol exhibited anticonvulsant profile in some experimental seizures 
such as MES and PTZ tests (Consroe et al,1981; Dallmeier et al, 1981). 
 Modulation of glutaminergic and gabaminergic transmission is one of the possible mechanisms 
indicated for anticonvulsant action of the terpenes like linalool and eugenol (Wie et al, 1981). Hence, it is 
possible that the anticonvulsant effects of O. majorana may be related in part to terpenes and terpenoid 
compounds present in the extracts. 
 The mechanism of anticonvulsant activity of the extracts is not clear. The quantity of ursolic acid 
present in all extracts is revealed by HPTLC analysis. TAF showed good anticonvulsant activity as it contains 
more amount of ursolic acid (1.18 %w/w of TAF) compared to the test extracts. Ursolic acid has been reported 
to have some effect on CNS. In a study, it was demonstrated that the ursolic acid of O. majorana appeared to be 
a potent acetyl cholinesterase inhibitor in Alzeimer’s Disease (Yo-Kyung Chung et al, 2001). As Alzeimer’s 
disease is related to CNS, it is possible that the ursolic acid may be responsible for the anticonvulsant activity of 
O. majorana extracts.  
 The results of the study revealed that O. majorana has potential anticonvulsant activity. However 
detailed experimental studies should be performed to elucidate the mechanism of action and to support this 
suggestion. The constituents like terpenoids and ursolic acid can be further explored to be the probable active 
constituents. 
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LIST OF NON-STANDARD ABBREVIATIONS 
PEOM: Pet ether extract of O. majorana 
CEOM: Chloroform extract O. majorana 
ACEOM: Acetone extract O. majorana 
MEOM: Methanol extract O. majorana 
AQEOM: Aqueous extract O. majorana 
TAF: Triterpenoic acid fraction 
